Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 23rd Annual Global Healthcare

Group 1 - China's advancements in biotech, particularly in immunology and cell therapy, have been significant, indicating a competitive landscape for companies like Immunocore [1] - Immunocore's competitive advantage lies in its TCR (T-cell receptor) platform, which is central to its development strategy [1] - The company acknowledges the need to remain vigilant and innovative, avoiding complacency in the rapidly evolving biotech field [2]